Bortezomib and Fludarabine With or Without Rituximab in Treating Patients With Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia

Inclusion Criteria:

* Diagnosis of chronic lymphocytic leukemia (CLL) OR indolent non-Hodgkin's lymphoma (NHL) of any of the following subtypes:

  * Follicular lymphoma:

    * Grade I follicular small cleaved cell;
    * Grade II follicular mixed cell;
    * Grade II follicular large cell;
    * Diffuse small cleaved cell;
    * Small lymphocytic lymphoma;
    * Lymphoplasmacytic lymphoma (Waldenstrom's macroglobulinemia)
* AND

  * Extranodal marginal zone B-cell lymphoma (mucosa-associated lymphoid tissue \[MALT\] lymphoma);
  * Nodal marginal zone B-cell lymphoma (monocytoid B-cell lymphoma);
  * Splenic marginal zone lymphoma (splenic lymphoma with villous lymphocytes);
  * Mantle cell lymphoma:

    * No blastic phase mantle cell lymphoma
* Relapsed or refractory, progressive disease:

  * First, second, or third relapse
* Measurable disease, meeting 1 of the following criteria:

  * At least 1 unidimensionally measurable lesion at least 20 mm by conventional techniques OR at least 10 mm by spiral CT scan (for NHL patients);
* OR:

  * Lymphocytosis \> 50,000/mm3 OR evidence of progressive bone marrow infiltration failure (e.g., hemoglobin 10 g/dL) OR thrombocytopenia (i.e., platelet count \< 100,000/mm3) with \> 30% infiltration of bone marrow by leukemia (for CLL patients)
* No measurable lymphadenopathy (for CLL and Waldenstrom's macroglobulinemia patients)
* No evidence of CNS lymphoma
* Performance status:

  * ECOG 0-2
* Life expectancy:

  * More than 12 weeks
* No history of uncontrolled orthostatic hypotension
* No symptomatic congestive heart failure
* No unstable angina pectoris
* No cardiac arrhythmia
* Not pregnant or nursing
* Negative pregnancy test
* Fertile patients must use effective contraception
* HIV negative
* No uncontrolled concurrent illness
* No grade 2 or greater neuropathy
* No history of allergy or anaphylaxis to mannitol, bortezomib, fludarabine, or boron
* No ongoing or active infection
* No psychiatric illness or social situation that would preclude study compliance
* At least 4 weeks since prior monoclonal antibody (MoAB) therapy:

  * Patients who have received MoAB therapy within the past 3 months must have documented disease progression since receiving this therapy
* No prior allogeneic stem cell transplantation
* More than 4 weeks since prior chemotherapy
* Prior fludarabine allowed
* At least 1 week since prior steroids
* At least 3 months since prior radio-immunotherapy
* More than 4 weeks since prior radiotherapy
* No prior bortezomib
* Absolute neutrophil count at least 1,500/mm3
* Platelet count at least 75,000/mm3 (greater than 50,000/mm3 if lymphomatous bone marrow involvement is present)
* Bilirubin no greater than 2.0 mg/dL
* AST/ALT no greater than 4 times normal
* Creatinine clearance greater than 40 mL/min
* No other concurrent investigational agents or treatments for the malignancy
* No brain metastases
* OR:

Quantitation of IgM paraprotein (for Waldenstrom's macroglobulinemia patients)